HylaPharm Overview

  • Founded
  • 2010
  • Status
  • Private
  • Employees
  • 6
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $800K
Latest Deal Amount
  • Investors
  • 1

HylaPharm General Information


Developer of targeted cancer therapies and cancer drugs. The company specializes in the research and development of new cancer drugs for chemotherapeutic use.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 2029 Becker Drive
  • Suite 285
  • Lawrence, KS 66047
  • United States
+1 (785) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

HylaPharm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 01-Oct-2015 $800K 00.00 Completed Product In Beta Test
2. Angel (individual) 16-Dec-2013 00000 00000 Completed Startup
1. Grant 22-Jan-2013 $200K Completed Startup
To view HylaPharm’s complete valuation and funding history, request access »

HylaPharm Executive Team (4)

Name Title Board Seat Contact Info
Daniel Aires MD Chief Executive Officer
Andrew Hansen Ph.D President
Craig Paddock Chief Financial Officer
Laird Forrest Ph.D Founder, Chief Technology Officer and Board Member
To view HylaPharm’s complete executive team members history, request access »

HylaPharm Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HylaPharm Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Kansas Bioscience Authority Government Minority 000 0000 000000 0
To view HylaPharm’s complete investors history, request access »